Compare ESE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESE | IMVT |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.5B |
| IPO Year | 1994 | 2019 |
| Metric | ESE | IMVT |
|---|---|---|
| Price | $263.27 | $37.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $283.33 | $33.00 |
| AVG Volume (30 Days) | 176.2K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 193.15 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $37,000,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $6.99 | N/A |
| P/E Ratio | $70.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $193.68 | $14.58 |
| 52 Week High | $362.15 | $45.42 |
| Indicator | ESE | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 36.23 |
| Support Level | $260.73 | $23.66 |
| Resistance Level | $290.82 | $41.22 |
| Average True Range (ATR) | 7.31 | 1.40 |
| MACD | 0.35 | -0.42 |
| Stochastic Oscillator | 29.70 | 13.69 |
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.